REFERENCES
- Pisoschi AM, Pop, A. The role of antioxidants in the chemistry of oxidative stress: A review. Eur J Med Chem 2015; 97:55-74.
- Toledo-Pereyra LH, Lopez-Neblina F, Toledo AH. Reactive oxygen species and molecular biology of ischemia/reperfusion. Ann Transplant. 2004; 9:81-3.
- Lopez-Neblina F, Toledo AH, Toledo-Pereyra LH. Molecular biology of apoptosis in ischemia and reperfusion. J Invest Surg. 2005; 18:335-50.
- Toledo-Pereyra LH, Lopez-Neblina F, Reuben JS, Toledo AH, Ward PA. Selectin inhibition modulates Akt/MAPK signaling and chemokine expression after liver ischemia-reperfusion. J Invest Surg. 2004; 17:303-313.
- Chen H, Liang ZW, Wang ZH, Zhang, JP, Hu B, Xing XB, Cai WB. Akt activation and inhibition of Cytochrome C release: mechanistic insights into Leptin-promoted survival of type II alveolar epithelial cells. J Cell Biochem 2015; 116:2313-24.
- Izano M, Wei EK, Tai C, Swede H, Gregorich S, Harris TB, Klepin H, Satterfield S, Murphy R, Newman AB, Rubin SM, Braithwaite D. Chronic inflammation and risk of colorectal and other obesity-related cancers: The health, aging and body composition study. Int J Cancer 2015.
- Yang Y, Guo Y, Tan S, Ke B, Tao J, Liu H, Jiang J, Chen J, Chen G, Wu B. b-Arrestin 1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling. Nat Commun 2015; 6:1-14.
- Garber K. Energy deregulation: licensing tumors to grow. Science 2006; 312:1158-1159.
- Schindler A, Foley E. Hexokinase 1 blocks apoptotic signals at the mitochondria. Cellular Signalling 2013; 25:2685-2692.
- Lemeshko VV. VDAC electrons: 1. VDAC-hexo(gluco)kinase generator of the mitochondrial outer membrane potential. Biochim Biophys Acta 2014; 1838:1362-71.
- Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004; 15:4217-26.
- Majewski N, Nogueira V, Robey RB, Hay N. Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cel Biol 2004; 24:730-40.
- Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, Jha AK, Smolen GA, Clasquin MF, Robey RB, Hay N. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013; 12:213-28.
- Patra KC, Hay N. Hexokinase 2 as oncotarget. Oncotarget 2013; 4:1862-3.
- Guzman G, Chennuri R, Chan A, Rea B, Quintana A, Patel R, Xu PZ, Xie H, Hay N: Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma. Dig Dis Sci 2015; 60:420-6.
- Calmettes G, Ribalet B, John S, Korge P, Ping P, Weiss JN. Hexokinases and cardioprotection. J Mol Cell Cardiol 2015: 78:107-15.